Swiss biotechnology firm Selexis SA, a specialist developer of cell lines used in the production of therapeutic proteins, says it has signed a non-exclusive R&D deal with Merrimack Pharmaceuticals.
Under the terms of the deal, Merrimack, which is based in Massachusettes, USA, gains the rights to use Selexis' SURE technology platform, specifically in the development of mammalian cells lines. Financial terms of the agreement were not revealed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze